Safety and Tolerability of RPESC-derived RPE Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)

  • End date
    Sep 27, 2025
  • participants needed
  • sponsor
    Luxa Biotechnology, LLC
Updated on 4 October 2022


The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD.


RPESC-RPE-4W is Allogeneic RPE stem cell (RPESC)-derived RPE cells (RPESC-RPE) isolated from the RPE layer of human cadaveric eyes are transplanted under the macular.

This first-in-human Phase 1/2a open-label dose-escalation interventional study plans to enroll a total of 18 subjects

Condition Dry Age-related Macular Degeneration
Treatment RPESC-RPE-4W
Clinical Study IdentifierNCT04627428
SponsorLuxa Biotechnology, LLC
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Clinical diagnosis of dry AMD
Ability to understand and give informed consent
Adult male or female >55 years of age
Medically suitable to undergo vitrectomy and subretinal injection (>60% on Karnofsky scale)
Postmenopausal if female (expected to be common for the age limitation), or the female partner of a male subject unable to father children
If male, willing to use barrier and spermicidal contraception during the study

Exclusion Criteria

Allergy or hypersensitivity to dilation drops or fluorescein
Active major medical conditions limiting ability to participate in the study
Active malignancy or treatment with chemotherapy
Systemic immunosuppressant therapy within past six months
History of toxoplasmosis, retinal histoplasmosis or tuberculosis
Receipt of investigational product (IP) in a clinical trial within prior six months
Any other medical condition, which, in the Investigator's judgment, will interfere with the subject's ability to comply with the protocol, compromises subject safety, or interferes with the interpretation of the study results
Pregnant or nursing females
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note